| 1.31 -0.09 (-6.43%) | 10-23 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.36  |
1-year : | 2.89 |
| Resists | First : | 2.02 |
Second : | 2.48 |
| Pivot price | 1.54 |
|||
| Supports | First : | 1.28 |
Second : | 1.07 |
| MAs | MA(5) : | 1.42 |
MA(20) : | 1.62 |
| MA(100) : | 2.35 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 6.2 |
| RSI | RSI(14): 27.5 |
|||
| 52-week | High : | 15.5 | Low : | 1.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RGNT ] has closed below the lower bollinger band by 6.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ RGNT ] is to continue within current trading range. It is unclear right now based on current values. 78.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.42 - 1.43 | 1.43 - 1.44 |
| Low: | 1.27 - 1.28 | 1.28 - 1.29 |
| Close: | 1.29 - 1.31 | 1.31 - 1.32 |
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Fri, 23 Oct 2026
Regentis Biomaterials Ltd. Estimates – AMEX:RGNT - TradingView
Tue, 13 Oct 2026
A roughly 10-minute knee procedure crosses a U.S. trial enrollment threshold at Regentis (RGNT). - Stock Titan
Tue, 13 Oct 2026
Regentis Biomaterials (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International C - Benzinga
Tue, 29 Sep 2026
Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care - Benzinga
Mon, 17 Aug 2026
Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks - USA Today
Tue, 04 Aug 2026
Regentis Biomaterials Ltd. Revenue Breakdown – AMEX:RGNT - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|